Login | Register

GlaxoSmithKline Acquires Developer Of Vaccine Platform Technologies

Pharmaceutical giant GlaxoSmithKline (GSK) has just strengthened its vaccine business with the acquisition of Okairos AG, a developer of vaccine platform technologies, for 250 million euros (324 million US dollars). Okairos AG, based in Switzerland, developed a new technology which will play a crucial role in the development of new classes of therapeutic and new prophylactic vaccines...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *